Plasminogen Activator Inhibitor-1: A Common Denominator in Cardiovascular Disease

Journal of Investigative Medicine

Volumn 46, Issue 8, 1998, Pages 370-376

  Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERTENSION; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS;

EID: 0032185396     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Collen, D, Lijnen HR. The fibrinolytic system in man. Crit Rev Oncol Hematol 1986;4:249-301.
2. Lijnen, HR, Colleen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997;39:343-50.
3. Lijnen HR, Bachmann F, Colleen D, et al. Mechanisms of plasminogen activation. J Intern Med 1994;236:415-24.
4. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
5. van Mourik JA, Lawrene DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984;259:14914-21.
6. Pannekoek H, Veerman H, Lambers H, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986;5:2539-44.
7. Aertgeerts K, De Bondt HL, De Ranter C, Declerck PJ. A model of the reactive form of plasminogen activator inhibitor-1. J Struct Biol 1994;113-239-45.
8. Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64:907-13.
9. Declerck PJ, De Mol M, Alessi MC et al. Purification and characterization of a plasminogen activator inhibitor. J Cell Biochem 1986;32:273-80.
10. Loskutoff DJ, Ny T, Sawdey M, Lawrence D. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor. J Cell Biochem 1986; 32:273-80.
11. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97:37-46.
12. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994;72:44-53.
13. Declerck PJ, Alessi MC, Verstreken M, Kruitof EK, JuhanVague I, Colleen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-5.
14. Vaughn DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infaction. Circulation 1997;96:442-7.
15. Vaughn DE, Declerck PJ, Van Houtle E., De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits Circ Res 1990;67:1281-6.
16. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasinogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein.alpha 2-macroglobin receptor. Proc Natl Acad Sci U S A 1992;89:7422-6.
17. Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990;111:1283-91.
18. Keijer J, Ehrlich HJ, Linders M, Preissner KT, Pannekoek H. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator. J Biol Chem 1991;266:10700-7.
19. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor or tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163:1260-6.
20. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989;264:10396-401.
21. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74:222-8.
22. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor by the juman hepatocellular cell line Hep G2. Thromb Haemost 1988;60:491-4.
23. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
24. Feener EP, Northrup JM, Aiello LP, King GL. Angiotension II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-62.
25. Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988;176:609-16.
26. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in hte type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 1991;266:23048-52.
27. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinoly- sis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20-6.
28. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen-activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998;273:8225-31.
29. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
30. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991;11:183-90.
31. Angleton P, Chandler WL, Schmer G. Diurnal varaiation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
32. Andreotti F, Kluft C. Cicadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336-51.
33. Andreotti F, Davies GJ, Hackett DR, et al. Major cicadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death stroke. Am J Cardiol 1988;62:635-7.
34. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease (see comments). Circulation 1989;79:733-43.
35. Kurnik P. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995;91:1341-6.
36. Juhan-Vague I, Valadier J, Alessi MC et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72.
37. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
38. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
39. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ, Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the North wick Park Heart Study. Lancet 1993;342:1165-8.
40. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekensch DE. Endogenous tissue-type plasminogen activator and risk of myocaridal infarction Lancet 1993;341:1165-8.
41. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prosepective study of endogenous tissue plasmiogen activator and risk or stoke (see comments). Lancet 1994;343:940-3.
42. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992;89:6998-7002.
43. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1432-43.
44. Lupu F, Heim DA, Bachmann F, Humi M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterisclerosis, Thromb Vasc Biol 1995;15:1444-55.
45. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclertoci plaque. Arteriscler Thromb Vasc Biol 1996;16:539-45.
46. Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989;1:874-82.
47. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990;110:1361-7.
48. 3 binding to vitronectin (see comments). Nature 1996;383:441-3.
49. Xiao Q, Danton MJ, Witte DP et al. Plasminogen deficiency accelerates vessesl wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A 1997;94:10335-40.
50. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Larahg JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
51. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanbe heritable hyperlipidemic rabbit. Hypertension 1992;20:473-7.
52. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15:S65-72.
53. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infaction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
54. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
55. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-8.
56. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. Journal of Clinical Investigation 1995; 96:2515-20.
57. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of reninangiotensin inhibition. Kidney Int 1997;51:164-72.
58. Yamashita M, Darlington DN, Weeks EJ, Jones RO, Gann DS. Plasminogen activator inhibitor-1 rises after hemorrhage in rats. Am J Physiol 1995;268:E1065-9.
59. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition supresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93:1073-8
60. Pederson OD, Gram J, Bagger H, Keller N, Jespersen CT. Regulation of tissue-type plasminogen activator mediated fibrinolysis by plasminogen activator mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischemic heart disease: possible unfavorable effects of diuretics. Coron Artery Dis 1994;5:617-23.
61. Vaughan DE, Rouleau JL, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995;16:31-6.
62. Brown NJ, Vaughan DE. ACE inhibition decreases PAI-1 in the setting of an activated RAS. Hypertension 1997;30:514.
63. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
64. Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993;44:485-8.
65. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaiita K, Nishiyama K. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997;20:441-5
66. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992; 15:1156-67.
67. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12:647-56.
68. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40:405-12.
69. Anonymous. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
70. Hamsten AE, Per. Fibrinolysis and Atherosclerosis. Bailliere's Clin Haemotol 1995;8:345-63.
71. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 1998;97:2213-21.
72. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor I levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
73. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997;78:656-60.
74. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities (see comments). Circulation 1996;94:2057-63.
75. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-9.
76. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994;89:321-30.
77. Sironi L, Mussoni L, Prati L, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996;16:89-96.
78. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993;13:1822-8.
79. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
80. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regiments on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thrombo Vasc Biology 1997;17:3071-8.
81. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90.
82. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994;91:3670-4.
83. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995;91:1175-81.
84. Eitzman DT, Fay WP, Lawrence DA, et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995;95:2416-20.
85. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen